Colombia exports medical cannabis to Mexico for the first time


Pideka made the first commercial export of medical cannabis to Mexico and for the pharmaceutical industry, a market the company estimates could reach nearly $ 20 billion over the next five years. The company also expects to be a major player in Europe in two years, increasing the number of jobs in the country fivefold.

The delivery was from the indoor plants in Tocancipá to Mexico, where nearly a million potential patients are eligible for treatments with these components.

“This is a very important step that we have been able to take hand in hand with ProColombia and other companies in the Colombian government. This opens the door for us to consolidate ourselves in a market as important as the Mexican market and sell medicinal cannabis oil THC to the public or private sector. This can be used by the pharmaceutical industry to fight four fronts: chronic pain like arthritis, different types of epilepsy, insomnia, stress and anxiety, and reducing the side effects of chemotherapy in cancer treatments. The Mexican customer chose this product of Colombian origin because of production, quality and legislative issues, ”said Borja Sanz de Madrid, President of Pideka, a Colombian-based company that is part of the Canadian international holding company Ikanik Farms, the Spanish Canadian, North American and Latin American investment.

Read about Colombia’s first medical cannabis export to Mexico and read the latest world cannabis news with the mobile app.

ProColombia in support of the cannabis industry

The businessman estimates that he could export between $ 80 million and $ 100 million in medicinal cannabis from Colombia containing THC in the next two to three years, taking into account that a liter of the product can cost around $ 45,000.

ProColombia aims to support the cannabis industry in regulating, promoting investment, exporting and identifying opportunities in markets where regulation enables access to these products, such as Germany and the UK. In addition to profiles from other markets such as Peru, the USA, Spain and Brazil.

“This is a conservative range based on the amount of liters we have per year and which we will be increasing gradually. We see great demand in Mexico and also want to serve the European market, where we have already seen interest from pharmaceutical companies in Denmark and England. Once Asia has its first legalizations it could be a very important continent for demand.

With this in mind, we want to be one of the main players in the world thanks to our efficiency model, ”said the President of Pideka, a company with just over 30 employees that is expected to reach 150 jobs in 2022.

According to the Dane, between January and November 2020, the US, UK, Australia, Israel, Germany and Switzerland were the countries that bought the most medicinal cannabis from Colombia. The jump was exponential as over that period exports rose from $ 275,000 in 2019 to $ 4.7 million, growing over 1,600%.

__ __

(Selected image by Julianza via Pixabay)

DISCLAIMER: This article was written by a third party and does not reflect the opinion of Born2Invest, its management, its employees or its employees. Please read our disclaimer for more information.

This article may contain forward-looking statements. These forward-looking statements are generally identified by the words “believe,” “project,” “estimate,” “will,” “plan,” “will” and similar expressions. These forward-looking statements involve known and unknown risks and uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this website. Although the company may believe that its expectations are based on reasonable assumptions, actual results that the company may achieve could differ materially from forward-looking statements, which are made only as of the date of this document. Also, be sure to read this important information.

Published in Portafolio for the first time, a third-party provider translated and adapted the article from the original. In the event of discrepancies, the original has priority.

While we have made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or organization that relies on translated content does so at their own risk. Born2Invest is not liable for any loss resulting from such reliance on the accuracy or reliability of the translated information. If you would like to report an error or an inaccuracy in the translation, we recommend that you contact us.